JP2018522894A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018522894A5 JP2018522894A5 JP2018503533A JP2018503533A JP2018522894A5 JP 2018522894 A5 JP2018522894 A5 JP 2018522894A5 JP 2018503533 A JP2018503533 A JP 2018503533A JP 2018503533 A JP2018503533 A JP 2018503533A JP 2018522894 A5 JP2018522894 A5 JP 2018522894A5
- Authority
- JP
- Japan
- Prior art keywords
- trehalose
- melibiurose
- cordobiose
- gentiobiulose
- rutinulose
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 2
- QIGJYVCQYDKYDW-UHFFFAOYSA-N 3-O-alpha-D-mannopyranosyl-D-mannopyranose Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(CO)OC(O)C1O QIGJYVCQYDKYDW-UHFFFAOYSA-N 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- LGQKSQQRKHFMLI-SJYYZXOBSA-N (2s,3r,4s,5r)-2-[(3r,4r,5r,6r)-4,5,6-trihydroxyoxan-3-yl]oxyoxane-3,4,5-triol Chemical compound O[C@@H]1[C@@H](O)[C@H](O)CO[C@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O)OC1 LGQKSQQRKHFMLI-SJYYZXOBSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- LGQKSQQRKHFMLI-UHFFFAOYSA-N 4-O-beta-D-xylopyranosyl-beta-D-xylopyranose Natural products OC1C(O)C(O)COC1OC1C(O)C(O)C(O)OC1 LGQKSQQRKHFMLI-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-PZPXDAEZSA-N 4β-mannobiose Chemical compound O[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-PZPXDAEZSA-N 0.000 description 1
- PVXPPJIGRGXGCY-TZLCEDOOSA-N 6-O-alpha-D-glucopyranosyl-D-fructofuranose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)C(O)(CO)O1 PVXPPJIGRGXGCY-TZLCEDOOSA-N 0.000 description 1
- PVXPPJIGRGXGCY-DJHAAKORSA-N 6-O-alpha-D-glucopyranosyl-alpha-D-fructofuranose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@](O)(CO)O1 PVXPPJIGRGXGCY-DJHAAKORSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- GUBGYTABKSRVRQ-CUHNMECISA-N D-Cellobiose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-CUHNMECISA-N 0.000 description 1
- SQNRKWHRVIAKLP-UHFFFAOYSA-N D-xylobiose Natural products O=CC(O)C(O)C(CO)OC1OCC(O)C(O)C1O SQNRKWHRVIAKLP-UHFFFAOYSA-N 0.000 description 1
- AYRXSINWFIIFAE-SCLMCMATSA-N Isomaltose Natural products OC[C@H]1O[C@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)[C@@H](O)[C@@H](O)[C@@H]1O AYRXSINWFIIFAE-SCLMCMATSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- NBGXQZRRLOGAJF-UHFFFAOYSA-N Maltulose Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)(CO)OCC1O NBGXQZRRLOGAJF-UHFFFAOYSA-N 0.000 description 1
- DKXNBNKWCZZMJT-UHFFFAOYSA-N O4-alpha-D-Mannopyranosyl-D-mannose Natural products O=CC(O)C(O)C(C(O)CO)OC1OC(CO)C(O)C(O)C1O DKXNBNKWCZZMJT-UHFFFAOYSA-N 0.000 description 1
- AYRXSINWFIIFAE-UHFFFAOYSA-N O6-alpha-D-Galactopyranosyl-D-galactose Natural products OCC1OC(OCC(O)C(O)C(O)C(O)C=O)C(O)C(O)C1O AYRXSINWFIIFAE-UHFFFAOYSA-N 0.000 description 1
- OVVGHDNPYGTYIT-VHBGUFLRSA-N Robinobiose Natural products O(C[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](O)O1)[C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](C)O1 OVVGHDNPYGTYIT-VHBGUFLRSA-N 0.000 description 1
- HIWPGCMGAMJNRG-ACCAVRKYSA-N Sophorose Natural products O([C@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O)[C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HIWPGCMGAMJNRG-ACCAVRKYSA-N 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 1
- DRQXUCVJDCRJDB-UHFFFAOYSA-N Turanose Natural products OC1C(CO)OC(O)(CO)C1OC1C(O)C(O)C(O)C(CO)O1 DRQXUCVJDCRJDB-UHFFFAOYSA-N 0.000 description 1
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 1
- HDTRYLNUVZCQOY-BTLHAWITSA-N alpha,beta-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-BTLHAWITSA-N 0.000 description 1
- HDTRYLNUVZCQOY-NCFXGAEVSA-N beta,beta-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-NCFXGAEVSA-N 0.000 description 1
- QLTSDROPCWIKKY-PMCTYKHCSA-N beta-D-glucosaminyl-(1->4)-beta-D-glucosamine Chemical compound O[C@@H]1[C@@H](N)[C@H](O)O[C@H](CO)[C@H]1O[C@H]1[C@H](N)[C@@H](O)[C@H](O)[C@@H](CO)O1 QLTSDROPCWIKKY-PMCTYKHCSA-N 0.000 description 1
- DLRVVLDZNNYCBX-ZZFZYMBESA-N beta-melibiose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](O)O1 DLRVVLDZNNYCBX-ZZFZYMBESA-N 0.000 description 1
- HIWPGCMGAMJNRG-UHFFFAOYSA-N beta-sophorose Natural products OC1C(O)C(CO)OC(O)C1OC1C(O)C(O)C(O)C(CO)O1 HIWPGCMGAMJNRG-UHFFFAOYSA-N 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- DLRVVLDZNNYCBX-CQUJWQHSSA-N gentiobiose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)C(O)O1 DLRVVLDZNNYCBX-CQUJWQHSSA-N 0.000 description 1
- 150000002276 gentiobiuloses Chemical class 0.000 description 1
- DLRVVLDZNNYCBX-RTPHMHGBSA-N isomaltose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)C(O)O1 DLRVVLDZNNYCBX-RTPHMHGBSA-N 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- JCQLYHFGKNRPGE-FCVZTGTOSA-N lactulose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 JCQLYHFGKNRPGE-FCVZTGTOSA-N 0.000 description 1
- 229960000511 lactulose Drugs 0.000 description 1
- PFCRQPBOOFTZGQ-UHFFFAOYSA-N lactulose keto form Natural products OCC(=O)C(O)C(C(O)CO)OC1OC(CO)C(O)C(O)C1O PFCRQPBOOFTZGQ-UHFFFAOYSA-N 0.000 description 1
- QIGJYVCQYDKYDW-LCOYTZNXSA-N laminarabiose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@H]1[C@H](O)[C@@H](CO)OC(O)[C@@H]1O QIGJYVCQYDKYDW-LCOYTZNXSA-N 0.000 description 1
- JCQLYHFGKNRPGE-HFZVAGMNSA-N maltulose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JCQLYHFGKNRPGE-HFZVAGMNSA-N 0.000 description 1
- QIGJYVCQYDKYDW-NSYYTRPSSA-N nigerose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](CO)OC(O)[C@@H]1O QIGJYVCQYDKYDW-NSYYTRPSSA-N 0.000 description 1
- 230000001603 reducing effect Effects 0.000 description 1
- OVVGHDNPYGTYIT-BNXXONSGSA-N rutinose Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](O)O1 OVVGHDNPYGTYIT-BNXXONSGSA-N 0.000 description 1
- 150000003308 rutinuloses Chemical class 0.000 description 1
- PZDOWFGHCNHPQD-VNNZMYODSA-N sophorose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](C=O)O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O PZDOWFGHCNHPQD-VNNZMYODSA-N 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- RULSWEULPANCDV-PIXUTMIVSA-N turanose Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](C(=O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O RULSWEULPANCDV-PIXUTMIVSA-N 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP15177544.2 | 2015-07-20 | ||
| EP15177544.2A EP3120842A1 (en) | 2015-07-20 | 2015-07-20 | Peritoneal therapeutic fluid |
| PCT/EP2016/067186 WO2017013120A1 (en) | 2015-07-20 | 2016-07-19 | Peritoneal therapeutic fluid |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018522894A JP2018522894A (ja) | 2018-08-16 |
| JP2018522894A5 true JP2018522894A5 (show.php) | 2018-12-13 |
| JP6448847B2 JP6448847B2 (ja) | 2019-01-09 |
Family
ID=53785450
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018503533A Active JP6448847B2 (ja) | 2015-07-20 | 2016-07-19 | 腹膜治療液及び腹膜治療液容器 |
Country Status (23)
| Country | Link |
|---|---|
| US (2) | US20180221303A1 (show.php) |
| EP (2) | EP3120842A1 (show.php) |
| JP (1) | JP6448847B2 (show.php) |
| KR (2) | KR102266889B1 (show.php) |
| CN (2) | CN107921009B (show.php) |
| AU (1) | AU2016296216B2 (show.php) |
| BR (1) | BR112018001005B1 (show.php) |
| CA (1) | CA2990532C (show.php) |
| CO (1) | CO2018000236A2 (show.php) |
| CY (1) | CY1124467T1 (show.php) |
| DK (1) | DK3324951T3 (show.php) |
| ES (1) | ES2880796T3 (show.php) |
| HR (1) | HRP20211319T1 (show.php) |
| HU (1) | HUE055208T2 (show.php) |
| LT (1) | LT3324951T (show.php) |
| MX (1) | MX387020B (show.php) |
| PL (1) | PL3324951T3 (show.php) |
| PT (1) | PT3324951T (show.php) |
| RS (1) | RS62142B1 (show.php) |
| RU (1) | RU2718908C2 (show.php) |
| SI (1) | SI3324951T1 (show.php) |
| SM (1) | SMT202100428T1 (show.php) |
| WO (1) | WO2017013120A1 (show.php) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3381484A1 (en) * | 2017-03-31 | 2018-10-03 | Opterion Health AG | Carbohydrate composition for dialysis |
| CN108310005A (zh) * | 2018-04-18 | 2018-07-24 | 浙江天瑞药业有限公司 | 一种抗腹膜纤维化的腹膜透析液 |
| AU2019360206B2 (en) * | 2018-10-16 | 2025-07-10 | President And Fellows Of Harvard College | SIRT1 activating compounds |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2155910C (en) * | 1995-08-11 | 1999-12-14 | George Wu | Biocompatible aqueous solution for use in continuous ambulatory peritoneal dialysis |
| JP2003507345A (ja) * | 1999-08-10 | 2003-02-25 | エムエル ラボラトリーズ ピーエルシー | デキストリン溶液を使用した治療薬剤の送達方法 |
| CA2382864A1 (en) * | 1999-10-15 | 2001-04-26 | The Dow Chemical Company | Dialysis solution including polyglycol osmotic agent |
| JP4882054B2 (ja) | 2000-09-13 | 2012-02-22 | 独立行政法人科学技術振興機構 | 腹膜透析液およびその調製法 |
| AU2002341566A1 (en) * | 2001-08-16 | 2003-04-01 | Mucosal Therapeutics, Inc. | Treatment and prevention of mucositis in cancer patients |
| GB0200704D0 (en) * | 2002-01-14 | 2002-02-27 | Britannia Pharmaceuticals Ltd | Use of phospholipids in peritoneal dialysis |
| ITRM20020562A1 (it) * | 2002-11-06 | 2004-05-07 | Sigma Tau Ind Farmaceuti | Uso del resveratrolo per la preparazione di un medicamento utile per il trattamento delle infezioni da virus dell'influenza. |
| SE524530C2 (sv) * | 2002-12-10 | 2004-08-24 | Gambro Lundia Ab | Metod för att framställa en medicinsk lösning för peritonealdialys där en lösning innehållandes ett eller flera acetylerade eller deacetylerade aminosocker värme- eller strålningssteriliseras med bestämda pH-värden och med bestämda viktsprocent för att undvika att cytotoxiska produkter bildas. |
| WO2005049049A1 (en) * | 2003-11-17 | 2005-06-02 | Braintree Laboratories, Inc. | Therapeutic peg solution concentrate |
| US7498341B2 (en) | 2004-01-31 | 2009-03-03 | Sanofi Aventis Deutschland Gmbh | Heterocyclically substituted 7-amino-4-quinolone-3-carboxylic acid derivatives, process for their preparation and their use as medicaments |
| US7384558B2 (en) | 2004-07-26 | 2008-06-10 | Baxter International Inc. | Compositions capable of inhibiting reactive oxygen and carbonyl species |
| US20060292099A1 (en) * | 2005-05-25 | 2006-12-28 | Michael Milburn | Treatment of eye disorders with sirtuin modulators |
| EP1993522A2 (en) | 2005-10-26 | 2008-11-26 | Kao Corporation | Resveratrol and/or grape leaf extract as i.a. endurance improver, anti-aging agent, muscle strength improver |
| US20090035240A1 (en) * | 2007-07-31 | 2009-02-05 | Maes Daniel H | Aqueous Based Cosmetic Compositions Containing Resveratrol Derivatives And An Aqueous Phase Structuring Agent |
| ES2685094T3 (es) * | 2007-07-31 | 2018-10-05 | Elc Management Llc | Composiciones cosméticas que contienen resveratrol |
| AU2009319870A1 (en) * | 2008-11-26 | 2011-07-14 | Lipoprotein Technologies, Inc. | Enhanced bioactive formulations of resveratrol |
| EP2381935B1 (en) * | 2009-01-19 | 2016-06-01 | Lycored Ltd. | Synergistic combinations of carotenoids and polyphenols |
| US8637569B2 (en) | 2009-10-22 | 2014-01-28 | Api Genesis, Llc | Methods of increasing solubility of poorly soluble compounds and methods of making and using formulations of such compounds |
| ES2365429B1 (es) * | 2010-03-05 | 2012-09-06 | Universidad De Castilla De La Mancha | Solucion para dialisis peritoneal |
| EP2609918A1 (en) * | 2011-12-27 | 2013-07-03 | Zytoprotec GmbH | Peritoneal dialysis fluid comprising a GSK-3 inhibitor |
| BR112014026616A2 (pt) * | 2012-04-24 | 2017-06-27 | Univ British Columbia | dialisado à base de polímero |
| EP2695606A1 (en) * | 2012-08-09 | 2014-02-12 | ETH Zürich | Liposome composition for peritoneal dialysis |
| ITRM20130135A1 (it) * | 2013-03-06 | 2014-09-07 | Michele Azzolini | Nuovi derivati del resveratrolo. |
| CN103330715B (zh) * | 2013-07-01 | 2015-09-02 | 华仁药业股份有限公司 | 一种抗腹膜纤维化的腹膜透析液 |
-
2015
- 2015-07-20 EP EP15177544.2A patent/EP3120842A1/en not_active Withdrawn
-
2016
- 2016-07-19 KR KR1020197006327A patent/KR102266889B1/ko active Active
- 2016-07-19 BR BR112018001005-7A patent/BR112018001005B1/pt active IP Right Grant
- 2016-07-19 JP JP2018503533A patent/JP6448847B2/ja active Active
- 2016-07-19 HR HRP20211319TT patent/HRP20211319T1/hr unknown
- 2016-07-19 US US15/745,903 patent/US20180221303A1/en not_active Abandoned
- 2016-07-19 PL PL16739518T patent/PL3324951T3/pl unknown
- 2016-07-19 CA CA2990532A patent/CA2990532C/en active Active
- 2016-07-19 CN CN201680042681.5A patent/CN107921009B/zh active Active
- 2016-07-19 SI SI201631288T patent/SI3324951T1/sl unknown
- 2016-07-19 LT LTEP16739518.5T patent/LT3324951T/lt unknown
- 2016-07-19 DK DK16739518.5T patent/DK3324951T3/da active
- 2016-07-19 CN CN201910196687.3A patent/CN110075307A/zh active Pending
- 2016-07-19 ES ES16739518T patent/ES2880796T3/es active Active
- 2016-07-19 EP EP16739518.5A patent/EP3324951B1/en active Active
- 2016-07-19 RU RU2018106122A patent/RU2718908C2/ru active
- 2016-07-19 PT PT167395185T patent/PT3324951T/pt unknown
- 2016-07-19 WO PCT/EP2016/067186 patent/WO2017013120A1/en not_active Ceased
- 2016-07-19 HU HUE16739518A patent/HUE055208T2/hu unknown
- 2016-07-19 AU AU2016296216A patent/AU2016296216B2/en active Active
- 2016-07-19 MX MX2018000336A patent/MX387020B/es unknown
- 2016-07-19 SM SM20210428T patent/SMT202100428T1/it unknown
- 2016-07-19 KR KR1020187001830A patent/KR20180048577A/ko not_active Ceased
- 2016-07-19 RS RS20210925A patent/RS62142B1/sr unknown
-
2018
- 2018-01-12 CO CONC2018/0000236A patent/CO2018000236A2/es unknown
-
2019
- 2019-09-27 US US16/586,113 patent/US11160766B2/en active Active
-
2021
- 2021-08-13 CY CY20211100731T patent/CY1124467T1/el unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112016015422A2 (pt) | formulações de vacina de frasco único | |
| BR112018001572A2 (pt) | método para induzir uma resposta imune, antígeno, adenovírus, uso de um antígeno e de um adenovírus, e, polinucleotídeo. | |
| EA201490610A1 (ru) | Соединения и способы усиления врожденных иммунных ответов | |
| CL2010000520A1 (es) | Forma cristalina del propanoato de (s) - isopropil 2 -(((s) - (((2r,3r,4r,5r) - 5- (2,4-dioxo-3,4-dihidropirimidim-1(2h) -il)-4-fluoro-3-hidroxi-4-metitetrahidrofuran-2-il)metoxi)(fenoxi)fosforil)amino); proceso de preparacion; composicion framaceutica; y su uso para el tratamiento de una infeccion causada por el virus de la hepatitis c. | |
| MA38675A1 (fr) | Dérivés de nucléosides 4'-fluoro-2'-méthyle substitués utiles pour inhiber la replication de l'hepatite c (hcv) | |
| EA201590890A1 (ru) | Производные 5-фтор-n-(пиридин-2-ил)пиридин-2-амина, содержащие сульфоксиминовую группу | |
| EA201892735A1 (ru) | Состав вакцины против hiv | |
| HK1257628A1 (zh) | 治療沙粒病毒科和冠狀病毒科病毒感染的方法 | |
| EA201491754A1 (ru) | Вакцина против rsv | |
| AR092401A1 (es) | Formulaciones de anticuerpos anti-receptor de prolactina (anti-prlr) | |
| HRP20201078T1 (hr) | Pripravci namijenjeni moduliranju eksprimiranja sod-1 | |
| JP2018522894A5 (show.php) | ||
| EA201791903A1 (ru) | β-D-2'-ДЕЗОКСИ-2'-α-ФТОР-2'-β-C-ЗАМЕЩЕННЫЕ-2-МОДИФИЦИРОВАННЫЕ-N6-ЗАМЕЩЕННЫЕ ПУРИНОВЫЕ НУКЛЕОТИДЫ ДЛЯ ЛЕЧЕНИЯ ВЫЗВАННЫХ HCV ЗАБОЛЕВАНИЙ | |
| EA201001491A1 (ru) | Репликационно-дефектные вакцины и вакцинные векторы против флавивирусов | |
| EP2268288A4 (en) | NUCLEOSIDE DERIVATIVES FOR THE TREATMENT OF CALICIVIRIDAE INFECTIONS, INCLUDING NOROVIRUS INFECTIONS | |
| FI2504353T4 (fi) | Lipopeptidikoostumukset ja vastaavat menetelmät | |
| MX378901B (es) | Formulaciones liquidas estables de virus de vacuna. | |
| BR112019010275A2 (pt) | adenovírus recombinante, composição, uso do adenovírus ou composição, método de induzir uma resposta imune em um paciente, e, adenovírus de símio não humano | |
| EA201391495A1 (ru) | Производные пиримидина для лечения вирусных инфекций | |
| BR112016013714A8 (pt) | compostos cristalinos de análogos de sofosbuvir antivirais, uso dos mesmos e composição farmacêutica | |
| CA2917096C (en) | Sulfoximine substituted 5-fluoro-n-(pyridin-2-yl)pyridin-2-amine derivatives and their use as cdk9 kinase inhibitors | |
| EP2854865A4 (en) | METHOD FOR THE TREATMENT OF METABOLIC SYNDROME BY MODULATION OF THE HEAT SHOCK PROTEIN (HSP) 90-BETA | |
| EA201790234A1 (ru) | 2'-хлораминопиримидиноновые и пиримидиндионовые нуклеозиды | |
| MX374124B (es) | Formulaciones de tampón para la estabilidad de anticuerpo mejorada. | |
| BRPI0923422A2 (pt) | promotor de reconstituição imunológica ou agente profilático para infecções cada um dos quais mantém o efeito enxerto-versus-tumor " |